About us

We operate from a 100,000 sq. ft. state-of-the-art, climate controlled growing facility

We hold GMP accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA) and GACP certification from the Control Union Medical Cannabis Standard (CUMCS). Our ambition is to develop cannabis-based medicines that are trusted by physicians and patients across Europe and globally.

Northern Leaf B roll 00 56 01 01 Still010

At a glance

€2.1bn by 2027

Europe’s pharmaceutical cannabis sector is expected to be worth €2.1bn by 2027, with demand in global markets expected to grow as further research is conducted into the medical benefits of cannabis. Northern Leaf targets these rapidly expanding markets, offering high-quality medicinal cannabis to support the manufacture of innovative new therapies.

100,000 sq.ft facility in Jersey

Operating from a state-of-the-art, 100,000 sq.ft. facility in Jersey, Northern Leaf benefits from a supportive local regulatory regime, high-quality local labour, low energy costs and good agricultural growing conditions.

International reach

The Company is one of only two UK growers to hold Home Office, MHRA and EU-GMP accreditations, enabling it to cultivate, grow, harvest and export its product internationally. This combination of regulatory and licensing approvals creates a significant competitive barrier to entry, essential to meet necessary production and operational standards demanded by the sector.

High grade quality

Northern Leaf’s cannabis has already displayed itself as a consistent, high-grade pharmaceutical product after several successful cycles – a pre-requisite for targeting cannabis growth markets and key enabler for commercial success.

Experts in growing

The Company’s management and operating team has deep experience and expertise across the pharmaceutical, commercial, political and horticultural sectors. The team is focused on building a sustainably profitable business, scaling operations in line with demand and not ahead of it.

Nl plant

Our experience

Northern Leaf has diverse team of experts, with many years of experience in their chosen fields

Our team is united in its ambition to develop the Company as a high-quality, consistent pharmaceutical-grade medical cannabis business serving the rapidly expanding local and international markets. We are passionate about regulated access to medical cannabis and helping patients to improve their quality of life.

Nl map

Vision and Strategy

Our ambition is to develop pharmaceutical grade cannabis based medicines that are trusted by doctors and patients across Europe and internationally

We aim to build a high growth, profitable business that has regulatory compliance, quality, sustainability and patient access at the heart of everything it does. We have and will continue to operate with the highest levels of integrity with all stakeholders, including government, medical regulators, employees, patients, customers and suppliers.

Our People

Senior Management


Geoff Eyre



Campbell Dunlop

Chief Operating Office


Asaf Shaked

Head of Cultivation


Paul McCabe

Head of Quality & Regulatory Affairs


David Waldenberg

Head of Business Development


Ashlea Stewart

Head of Sales

Our People

The Board


Frank Walker OBE

Independent Non-Executive Chairman


Geoff Eyre


Katie headshot

Katie Shelton-Innes

Non-Executive Director

Mike t

Michael Thompson

Independent Non-Executive Director


Tobias Mathews

Non-Executive Director

Where we’ve been

A timeline of our progress

Nl plant


+ Raised £2.1m series A equity at a £20m pre-money valuation

Nl map


+ Hemp licence awarded by the Government of Jersey to prove concept

Nl timline 2


Awarded first full commercial THC licence by the Government of Jersey in December 2020

Northern Leaf B roll 00 42 14 12 Still004 1


Raised £14.2m to fund expansion and medical cannabis refit

Northern Leaf B roll 03 00 41 09 Still069


Phase 1 facility medical cannabis facility complete

Screenshot 2023 09 05 at 11 36 22


GMP and GACP accreditations awarded

We are dedicated to serving patients to help improve their quality of life and everything we do is with this in mind – ensuring that we produce high-quality, consistent medicines, underpinned by regulatory compliance and sustainability.